Aligos Therapeutics, Inc. (ALGS:NASDAQ) closed at $5.26 on October 14, 2026, down 4.43% on the day. The stock trades 61.6% below its 52-week high of $13.69 and 32.2% above its 52-week low of $3.98. Over the past year, it lost 43.0%. Aligos Therapeutics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +3.18% | +9.33% | -4.17% | -17.52% | -42.96% |
In 252 trading sessions since October 13, 2025, ALGS closed higher on 124 days (49%). Its best day was August 10, 2026 (+36.85%) and its worst was August 31, 2026 (-15.20%). The stock moved 10% or more in a single session 15 times.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Find more stocks like ALGS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.